{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-003030","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.514859+00:00","generated_at":"2026-05-16T11:05:44.513559+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NKGen Biotech enters $25.84M secured promissory note with AlpineBrook at 12% interest","bullets":["Note principal $25,840,106; 12% interest; initial maturity 2 months, extendable at lender's sole discretion.","Note documents $25,540,106 in prior advances plus $300,000 new cash; no prepayment without lender consent.","Includes most-favored-nation clause; security interests in US personal/real property and NKGen Korea shares.","Change of control triggers 20% prepayment premium; restrictive covenants limit additional debt and liens.","Security interests subordinated to East West Bank and BDW Investments liens; Korean share pledge after July 2026 lock-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-003030","json":"https://secwatch.observer/filing/0001213900-26-003030.json","markdown":"https://secwatch.observer/filing/0001213900-26-003030.md","text":"https://secwatch.observer/filing/0001213900-26-003030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/0001213900-26-003030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/ea0272061-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:05:44.513559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69ccfb7482985dd9b1a48d63c08c0abf7128c1a3","claim":"NKGen Biotech, Inc. incurred loan of $25,840,106 with AlpineBrook Capital GP I Limited at 12% per annum maturing initially on the date falling two months after issuance, subject to extension at the Lender’s discretion.","evidence_excerpt":"On January 5, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation (the “ Company Sub ,” and together with the Company, the “ Borrowers ”), entered into a secured promissory note (the “ Note ”) with AlpineBrook Capital GP I Limited (the “ Lender ”), in the original principal amount of $25,840,106, bearing interest at 12% per annum and maturing initially on the date falling two months after issuance, subject to extension at the Lender’s discretion.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/0001213900-26-003030-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$25,840,106"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Rate","value":"12% per annum"},{"label":"Maturity","value":"initially on the date falling two months after issuance, subject to extension at the Lender’s discretion"},{"label":"Event","value":"incurrence"}]},{"claim_id":"6d4e3638b9bbb348ab2dab3a473ae33d198c5b6d","claim":"NKGen Biotech, Inc. entered into Note with AlpineBrook Capital GP I Limited valued at original principal amount of $25,840,106 (effective 2026-01-05).","evidence_excerpt":"On January 5, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation (the “ Company Sub ,” and together with the Company, the “ Borrowers ”), entered into a secured promissory note (the “ Note ”) with AlpineBrook Capital GP I Limited (the “ Lender ”), in the original principal amount of $25,840,106, bearing interest at 12% per annum","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/0001213900-26-003030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Value","value":"original principal amount of $25,840,106"},{"label":"Effective","value":"2026-01-05"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}